Τρίτη 20 Οκτωβρίου 2020

 


Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer.
Conclusions Prostate tumors of AAM manifest a unique immune repertoire and have significant enrichment of pro-inflammatory immune pathways that are associated with poorer outcomes. Observed immune-oncologic differences can aide in a genomically adaptive approach to treating PCa in AAM. PMID: 33037017 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
5d
Noninvasive Detection of Urothelial Carcinoma by Cost-effective Low-coverage Whole-genome Sequencing from Urine-Exfoliated Cell DNA.
CONCLUSIONS: UroCAD could be a robust urothelial carcinoma diagnostic method with improved sensitivity and similar specificity as compared with cytology tests. It may be used as a noninvasive approach for diagnosis and recurrence surveillance in urothelial carcinoma prior to the use of cystoscopy, which would largely reduce the burden on patients. PMID: 33037018 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
5d
Project Orbis: Global Collaborative Review Program.
Authors: de Claro RA, Spillman D, Hotaki LT, Shum M, Mouawad LS, Santos GML, Robinson K, Hunt M, Healy C, Chan A, Looi YH, Rodrigues C, Rohr UP, Walther C, Pazdur R Abstract In 2019, the FDA Oncology Center of Excellence (OCE) launched Project Orbis, a global collaborative review program to facilitate faster patient access to innovative cancer therapies across multiple countries. Project Orbis aims for concurrent submission, review, and regulatory action for high-impact clinically significant...
Clinical Cancer Research
5d
CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma.
CONCLUSIONS: This first-in-human study demonstrates the tolerability, safety, and encouraging efficacy of CD19-PD-1/CD28-CART in PD-L1+ large B-cell lymphoma. PMID: 33028589 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Development and validation of a next-generation sequencing-based multigene assay to predict the prognosis of estrogen receptor-positive, HER2-negative breast cancer.
CONCLUSIONS: The newly developed and validated NGS-based multigene assay can predict the distant recurrence risk in ER-positive, HER2-negative breast cancer. PMID: 33028590 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Spatiotemporal Heterogeneity in Multiparametric Physiologic MRI Are Associated with Patient Outcomes in IDH-wildtype Glioblastoma.
CONCLUSIONS: Hypovascular cellular habitats derived from multiparametric physiologic MRIs may be useful predictors of clinical outcomes in patients with post-treatment glioblastoma. PMID: 33028594 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Preclinical comparison of the blood brain barrier (BBB) permeability of osimertinib with other EGFR TKIs.
Conclusion These preclinical studies indicate that osimertinib can achieve significant exposure in the brain compared with the other EGFR-TKIs tested and supports the ongoing clinical evaluation of osimertinib for the treatment of EGFRm brain metastasis. This work also demonstrates the link between low in-vitro transporter efflux ratios and increased brain penetrance in-vivo supporting the use of in-vitro transporter assays as an early screen in drug discovery. PMID: 33028591 [PubMed - as supplied...
Clinical Cancer Research
1w
Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence.
CONCLUSIONS: Plasma assay of novel CRC-associated MDMs can reliably detect primary CRC and distantly recurrent CRC with promising accuracy. PMID: 33028593 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
In-depth clinical and biological exploration of DNA Damage Immune Response (DDIR) as a biomarker for oxaliplatin use in colorectal cancer.
CONCLUSIONS: DDIR positivity does not predict improved response following oxaliplatin treatment in CRC. However, data presented here suggests the potential of the DDIR assay in identifying immune-rich tumours that may benefit from immune checkpoint blockade, beyond current use of MSI status. PMID: 33028592 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Improved survival associated with local tumor response following multi-site radiotherapy and pembrolizumab: secondary analysis of a phase I trial.
CONCLUSIONS: In the context of SBRT+P, TMC independently correlates with OS. SBRT impacts intratumoral immune gene expression associated with TMC. Randomized trials are needed to validate these findings. PMID: 33028595 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Effect of germline mutations in homologous recombination repair genes on overall survival of patients with pancreatic adenocarcinoma.
CONCLUSIONS: This study demonstrates that germline mutation carrier status in PDAC is associated with longer OS compared to non-carriers. Further research into tumor biology and response to platinum-based chemotherapy in germline mutation carriers with PDAC are needed to better understand the association with longer OS. PMID: 33028596 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
A Space-Time Continuum for Immunotherapy Biomarkers in Gastroesophageal Cancer?
Authors: Klempner SJ, Upadhyay V, Chao J Abstract In an annotated series of gastroesophageal adenocarcinomas differences in PD-L1 expression and TMB occur between both paired contemporaneous primary and metastatic biopsies and pre/post-treatment samples. This work has implications for optimizing patient selection, serial testing, need for mechanistic understanding, and may underlie variable responses to checkpoint inhibitors in gastroesophageal cancers. PMID: 33023951 [PubMed - as...
Clinical Cancer Research
1w
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-Risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is predictive of therapeutic response.
CONCLUSIONS: Low relative lesion volume at baseline mpMRI was predictive of pathologic response. A subset of patients had limited response. Selection of patients based on these metrics may improve outcomes in high-risk disease. PMID: 33023952 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Transcriptional subtypes resolve tumor heterogeneity and identify vulnerabilities to MEK inhibition in lung adenocarcinoma.
CONCLUSIONS: Our findings support forward translational relevance of transcriptional subtypes, where further exploration therein may improve lung adenocarcinoma treatment. PMID: 33023953 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Genome and transcriptome biomarkers of response to immune checkpoint inhibitors in advanced solid tumours.
CONCLUSIONS: Interpreting the tumour-immune interface to predict ICI efficacy remains challenging. WGTA allows for identification of multiple biomarkers simultaneously that in combination may help to identify responders, particularly in the context of a heterogeneous population of advanced and previously treated cancers, thus precluding tumour type-specific testing. PMID: 33020056 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Gene expression signatures of BRCAness and tumor inflammation define subgroups of early-stage hormone receptor-positive breast cancer patients.
CONCLUSIONS: BRCA-related DNA repair deficiency and suppressed tumor immune responses may be clinically relevant predictors of endocrine therapy complementing treatment options in subgroups of hormone-sensitive early breast cancer. PMID: 33008814 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma.
CONCLUSION: MYC rearrangement is associated with high disease burden and is an independent adverse prognostic factor in newly diagnosed MM. PMID: 33008815 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Interleukin-12 message in a bottle.
Authors: Cirella A, Berraondo P, Di Trani CA, Melero I Abstract IL-12 is a very potent cancer immunotherapy agent but is difficult to harness safely if given systemically. Local gene-transfer aims to confine the effects of IL-12 to malignant tissues, thus avoiding toxicity. Lipid-nanoparticled messenger RNA achieves IL-12 expression and efficacy in mouse models, opening the way to an ongoing trial. PMID: 33004432 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Selected Articles from This Issue.
Authors: PMID: 33004470 [PubMed - in process] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Next-Generation Sequencing of Cerebrospinal Fluid: How can a liquid be like a solid?
Authors: Marmarelis ME, Bauml JM Abstract The APOLLO investigators showed that NGS of cerebrospinal fluid can reveal molecular alterations - how should this affect our management approach? PMID: 32998958 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου